- Home
- CDMO
as 07-26-2024 4:00pm EST
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | TUSTIN |
| Market Cap: | 472.3M | IPO Year: | N/A |
| Target Price: | $12.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.07 - $13.24 | Next Earning Date: | 07-02-2024 |
| Revenue: | $139,911,000 | Revenue Growth: | -6.27% |
| Revenue Growth (this year): | 19.56% | Revenue Growth (next year): | 22.63% |
Stock Insider Trading Activity of Avid Bioservices Inc. (CDMO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Jul 12 '24 | Sell | $8.36 | 307 | $2,566.52 | 23,410 | SEC Form 4 |
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Jul 11 '24 | Sell | $8.05 | 119 | $957.95 | 22,836 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jul 10 '24 | Sell | $7.54 | 59 | $444.86 | 6,957 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jul 10 '24 | Sell | $7.54 | 1,456 | $10,978.24 | 33,290 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jul 9 '24 | Sell | $7.54 | 115 | $867.10 | 6,881 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jul 9 '24 | Sell | $7.54 | 910 | $6,861.40 | 30,699 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Apr 30 '24 | Sell | $7.40 | 1,005 | $7,436.50 | 27,132 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Apr 30 '24 | Sell | $7.40 | 109 | $806.60 | 5,353 | SEC Form 4 |
| Green Nicholas Stewart | CDMO | President & CEO | Apr 30 '24 | Sell | $7.40 | 11,762 | $87,028.21 | 203,606 | SEC Form 4 |
| Ziebell Mark R | CDMO | V. P., General Counsel | Apr 30 '24 | Sell | $7.40 | 1,643 | $12,157.05 | 64,834 | SEC Form 4 |
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Apr 30 '24 | Sell | $7.40 | 1,233 | $9,121.98 | 21,797 | SEC Form 4 |
| Hart Daniel R | CDMO | Chief Financial Officer | Apr 30 '24 | Sell | $7.40 | 2,826 | $20,910.42 | 82,221 | SEC Form 4 |
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Jan 11 '24 | Sell | $6.77 | 274 | $1,854.98 | 19,829 | SEC Form 4 |
| Kwietniak Matthew R. | CDMO | Chief Commercial Officer | Jan 9 '24 | Sell | $6.17 | 1,060 | $6,539.99 | 19,434 | SEC Form 4 |
| Ziebell Mark R | CDMO | V. P., General Counsel | Jan 9 '24 | Sell | $6.17 | 1,346 | $8,304.82 | 63,269 | SEC Form 4 |
| Hart Daniel R | CDMO | Chief Financial Officer | Jan 9 '24 | Sell | $6.17 | 2,408 | $14,856.64 | 79,305 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jan 9 '24 | Sell | $6.17 | 1,055 | $6,509.35 | 25,625 | SEC Form 4 |
| Richieri Richard A. | CDMO | Chief Operations Officer | Jan 9 '24 | Sell | $6.17 | 116 | $715.72 | 5,208 | SEC Form 4 |
| Hancock Richard B | CDMO | Director | Dec 14 '23 | Buy | $5.86 | 23,000 | $134,734.00 | 78,760 | SEC Form 4 |
| Hancock Richard B | CDMO | Director | Dec 13 '23 | Buy | $5.21 | 38,803 | $202,035.58 | 117,563 | SEC Form 4 |
Latest Avid Bioservices Inc. News
CDMO Breaking Stock News: Dive into CDMO Ticker-Specific Updates for Smart Investing
Insider Monkey
18 hours ago
Does Avid Bioservices (CDMO) have Hidden Potential Despite Current Weakness?
MT Newswires
24 days ago
Avid Bioservices Fiscal Q4 Loss Widens, Revenue Increases; Fiscal 2025 Revenue Outlook Set
GlobeNewswire
24 days ago
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
GlobeNewswire
a month ago
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
Simply Wall St.
a month ago
Those who invested in Avid Bioservices (NASDAQ:CDMO) five years ago are up 104%
Insider Monkey
a month ago
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare CDMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDMO Avid Bioservices Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.